We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Intercytex | LSE:ICX | London | Ordinary Share | GB00B0762609 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.125 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMICX RNS Number : 6686E Intercytex Group plc 23 December 2009 23 December 2009 Intercytex Group plc - result of General Meeting Intercytex Group plc (AIM: ICX) ("Intercytex") confirms that at the General Meeting held earlier today, all the Resolutions, set out in the circular sent to shareholders on 7 December 2009, were duly passed. Cancellation of admission to trading on AIM is therefore expected to occur at 7.00 a.m. on 8th January 2010. The Company's name will also be changed to Regenerative Medicine Assets Limited. In addition, as set out in the circular, Dr Paul Kemp and Dr Alan Suggett have resigned as directors of Intercytex, The Board wishes to thank both Alan and Paul for their contributions to the Company. - Ends - Enquiries For more information, contact: +--------------------------------------------+--------------------------------------------+ | Intercytex Group plc | | +--------------------------------------------+--------------------------------------------+ | Nick Higgins, Chief Executive Officer | Tel: 0161 904 4500 | +--------------------------------------------+--------------------------------------------+ | Max Herrmann, Chief Financial Officer | | +--------------------------------------------+--------------------------------------------+ | | | +--------------------------------------------+--------------------------------------------+ | Financial Dynamics | | +--------------------------------------------+--------------------------------------------+ | Jonathan Birt | Tel: 0207 269 7205 | +--------------------------------------------+--------------------------------------------+ | | | +--------------------------------------------+--------------------------------------------+ | Piper Jaffray Ltd | | +--------------------------------------------+--------------------------------------------+ | Neil Mackison | Tel: 0203 142 8700 | | Graeme Smethurst | | +--------------------------------------------+--------------------------------------------+ Intercytex' shares are listed on the Alternative Investment Market of the London Stock Exchange under the ticker symbol ICX.L. Additional information on the Company can be found at www.intercytex.com Statements contained within this press release may contain forward-looking information or statements with respect to the financial condition, results of operations and business achievements/performance of Intercytex and certain of the plans and objectives of management of Intercytex with respect thereto. By their nature, forward-looking statements involve risks and uncertainties that may cause actual results to vary from those contained in the forward-looking statements. In some cases, you can identify such forward-looking statements by terminology such as 'may', 'will', 'could', 'forecasts', 'expects', 'plans', 'anticipates', 'believes', 'estimates', 'predicts', 'potential', 'continue' or similar expressions. A number of factors, including the satisfactory progress of research and development, could cause Intercytex' actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements. Forward projections reflect management's best estimates based on information available at the time of issue and are not a guarantee of future performance. Other than as required by applicable law, Intercytex does not undertake any obligation to update or revise any forward-looking information or statements to reflect events or circumstances after the date of this release. The term "Intercytex" refers to Intercytex Group plc and its subsidiary undertakings. This information is provided by RNS The company news service from the London Stock Exchange END ROMEXLFLKLBXFBD
1 Year Intercytex Chart |
1 Month Intercytex Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions